PolTREG is preparing for the IPO

July 12th, 2021

The biotechnology company PolTREG S.A. develops modern drugs based on T-regulatory cells for the treatment of autoimmune diseases. Currently, it is runnning research and development projects at various stages of clinical advancement, including the treatment of type 1 diabetes in children and the treatment of multiple sclerosis. The goal is to create a platform for the treatment of various autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.

At the end of June, the company submitted a prospectus to the Polish Financial Supervision Authority (KNF) with the intention to conduct an initial public offering of shares and admit the shares to trading on the regulated market of the Warsaw Stock Exchange. The company’s stock exchange debut is planned for the fourth quarter of this year, and the funds raised will be used to finance the next stages of clinical trials. The business goal is to become one of the leaders in the global market for the treatment of autoimmune diseases with the use of T-regulatory cells.

Research and development is already very advanced. Phase I/II clinical trials in type 1 diabetes in children were successfully completed last year. After undergoing the Scientific Advice procedure with the European Medicines Agency, the phase II/III study in the treatment of patients with newly diagnosed type 1 diabetes is in preparation. The second test in type 1 diabetes will be the I/II clinical test to identify and treat the pre-symptomatic period patients at high risk due to genetic predispositions. This study is particularly promising as it may change the approach to diabetes treatment worldwide – currently screening and early treatment are not used due to the lack of available early-stage diabetes therapy. A phase I clinical trial in relapsing-remitting multiple sclerosis also has yielded very promising results.

The company is also developing its research facilities – by the end of the year PolTREG plans to complete the construction of a modern laboratory. The budget of the investment is PLN 23.7 million. After completing the construction of the laboratory, the team will increase from 20 to around 40 people.